ENTX
- Entera Bio Ltd.
()
Overview
Company Summary
Entera Bio Ltd. (ENTX) is a biotechnology company that focuses on the development and commercialization of orally delivered large molecule therapeutics for various diseases. The company utilizes its proprietary oral drug delivery technology platform, called the "EnteraNet�", to develop and deliver therapeutic proteins and peptides through the gastrointestinal tract.
ENTX's approach offers an alternative to traditional injection-based therapies for conditions such as osteoporosis, hyperparathyroidism, anemia, and more. By developing oral formulations for large molecules, the company aims to improve patient compliance, reduce treatment costs, and enhance the overall effectiveness of these therapeutics.
The EnteraNet� platform is designed to protect therapeutic proteins and peptides from degradation in the stomach and allow them to be absorbed in the small intestine efficiently. This technology enables ENTX to overcome the challenges associated with oral delivery of large molecules, which have historically been considered difficult to administer in this manner.
Aside from developing its own pipeline of proprietary oral drugs, ENTX also collaborates with pharmaceutical partners to apply its technology to their molecules. The company's versatile platform can potentially be applied to a wide range of therapeutic proteins and peptides, opening up opportunities for licensing and partnership agreements.
Overall, Entera Bio Ltd. is dedicated to revolutionizing drug delivery by providing novel oral formulations for large molecule therapeutics, ultimately improving patient outcomes and changing the way certain diseases are treated.